BioTuesdays

Tag - William Blair

WB starts Phreesia at OP

William Blair launched coverage of Phreesia (NYSE:PHR) with an “outperform” rating. The stock closed at $27.37 on Aug. 9. Phreesia, which went public in July 2019, gives healthcare organizations a suite of robust...

WB starts Addus HomeCare at OP

William Blair initiated coverage of Addus HomeCare (NASDAQ:ADUS) with an “outperform” rating, saying the company is one of the few ways for public market investors to play the in-home healthcare delivery theme, with a...

WB starts Actinium Pharma at OP

William Blair launched coverage of Actinium Pharmaceuticals (NASDAQ:ATNM) with an “outperform” rating based on its view that the company’s potent and specific radiopharmaceuticals for improving treatment options of...

WB cuts AxoGen to MP from OP

William Blair downgraded AxoGen (NASDAQ:AXGN) to “market perform” from “outperform” after the company reduced revenue guidance for 2019. The stock closed at $17.58 on Aug. 6, near the low end of its 52-week range of $14...

WB starts Change Healthcare at OP

William Blair launched coverage of Change Healthcare (NASDAQ:CHNG) with an “outperform” rating. The stock closed at $13.50 on July 19. Change Healthcare is a leading healthcare technology platform provider, offering...

Subscribe

Sign up to our weekly BioTuesdays newsletter.